Showing results (191-200 of 407) with videos related to
Sort By:
Pageof 41
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 8, 2009
Identification of novel kinase targets for the treatment of estrogen receptor-negative breast cancerCorey Speers, Anna Tsimelzon, Krystal Sexton, et al.BMC Cancer|August 27, 2011
A moderate elevation of circulating levels of IGF-I does not alter ErbB2 induced mammary tumorigenesisRobert K Dearth, Isere Kuiatse, Yu-Fen Wang, et al.BMC Cancer|June 15, 2012
Methylation of HIN-1, RASSF1A, RIL and CDH13 in breast cancer is associated with clinical characteristics, but only RASSF1A methylation is associated with outcomeJia Xu, Priya B Shetty, Weiwei Feng, et al.Journal of the National Cancer Institute|August 19, 1999
Loss of heterozygosity at D14S62 and metastatic potential of breast cancerP O'Connell, K Fischbach, S Hilsenbeck, et al.Cancer Research|September 17, 2008
Development of resistance to targeted therapies transforms the clinically associated molecular profile subtype of breast tumor xenograftsChad J Creighton, Suleiman Massarweh, Shixia Huang, et al.Clinical and Translational Science|May 7, 2010
Prevention of trauma/hemorrhagic shock-induced lung apoptosis by IL-6-mediated activation of Stat3Ana Moran, Anna I Tsimelzon, Mary-Ann A Mastrangelo, et al.Journal of Plastic, Reconstructive & Aesthetic Surgery : JPRAS|April 16, 2013
Predictors of post-mastectomy reconstruction in an underserved populationErik M Wolfswinkel, Santiago N Lopez, William M Weathers, et al.Journal of Pediatric Hematology/Oncology|August 26, 2000
MGI 114: augmentation of antitumor activity when combined with topotecanS Weitman, H Barrera, R Moore, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 28, 2000
Prognostic value of p53 for local failure in mastectomy-treated breast cancer patientsR C Zellars, S G Hilsenbeck, G M Clark, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 14, 1998
Preclinical and clinical strategies for development of telomerase and telomere inhibitorsS Sharma, E Raymond, H Soda, et al.Pageof 41